Literature DB >> 28251117

Hepatitis B and concomitant hepatic steatosis.

Chong Teik Lim1, Rajneesh Kumar1.   

Abstract

Hepatic steatosis is becoming more common in Asia with prevalence becoming as common as Western countries. Concomitant Hepatitis B and hepatic steatosis is increasingly encountered in clinical practice. The interaction between the two concomitant conditions at both molecular level and clinical outcome remains to be explored. The present review is aimed at summarizing the existing literature on the complex interaction of the two-concomitant disease.

Entities:  

Keywords:  Hepatitis B; NASH; fatty liver; hepatic steatosis; steatohepatitis

Year:  2017        PMID： 28251117      PMCID： PMC5326645          DOI： 10.21037/atm.2016.12.04

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


  31 in total

1.  Prevalence of the TM6SF2 variant and non-alcoholic fatty liver disease in Chinese.

Authors:  Vincent Wai-Sun Wong; Grace Lai-Hung Wong; Chi-Hang Tse; Henry Lik-Yuen Chan
Journal:  J Hepatol       Date:  2014-05-10       Impact factor: 25.083

2.  Prevalence of hepatic steatosis in chronic hepatitis B patients and its association with disease severity.

Authors:  Laurentius A Lesmana; C Rinaldi Lesmana; Levina S Pakasi; Ening Krisnuhoni
Journal:  Acta Med Indones       Date:  2012-01

3.  Dietary choline restriction causes complex I dysfunction and increased H(2)O(2) generation in liver mitochondria.

Authors:  K Hensley; Y Kotake; H Sang; Q N Pye; G L Wallis; L M Kolker; T Tabatabaie; C A Stewart; Y Konishi; D Nakae; R A Floyd
Journal:  Carcinogenesis       Date:  2000-05       Impact factor: 4.944

4.  Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection.

Authors:  Jun-ping Shi; Jian-gao Fan; Rui Wu; Xiao-qian Gao; Li Zhang; Hao Wang; Geoffrey C Farrell
Journal:  J Gastroenterol Hepatol       Date:  2008-09       Impact factor: 4.029

5.  Hepatic steatosis: prevalence and host/viral risk factors in Iranian patients with chronic hepatitis B infection.

Authors:  Vahdat Poortahmasebi; Seyed Moayed Alavian; Hossein Keyvani; Mehdi Norouzi; Mahmood Mahmoodi; Seyed Mohammad Jazayeri
Journal:  Asian Pac J Cancer Prev       Date:  2014

6.  Clinical and virological characteristics post HBsAg seroclearance in hepatitis B virus carriers with hepatic steatosis versus those without.

Authors:  Chia-Ming Chu; Deng-Yn Lin; Yun-Fan Liaw
Journal:  Dig Dis Sci       Date:  2012-08-18       Impact factor: 3.199

7.  Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B.

Authors:  Anthony W H Chan; Grace L H Wong; Hoi-Yun Chan; Joanna H M Tong; Yau-Hei Yu; Paul C L Choi; Henry L Y Chan; Ka-Fai To; Vincent W S Wong
Journal:  J Gastroenterol Hepatol       Date:  2017-03       Impact factor: 4.029

8.  The hepatitis B virus X protein inhibits secretion of apolipoprotein B by enhancing the expression of N-acetylglucosaminyltransferase III.

Authors:  Sung-Koo Kang; Tae-Wook Chung; Ji-Young Lee; Young-Choon Lee; Richard E Morton; Cheorl-Ho Kim
Journal:  J Biol Chem       Date:  2004-04-29       Impact factor: 5.157

9.  Impact of fatty liver on hepatitis B virus replication and virologic response to tenofovir and entecavir.

Authors:  Bahadır Ceylan; Ferhat Arslan; Ayşe Batırel; Muzaffer Fincancı; Cem Yardımcı; Esra Fersan; Esra Paşaoğlu; Mesut Yılmaz; Ali Mert
Journal:  Turk J Gastroenterol       Date:  2015-12-17       Impact factor: 1.852

10.  Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors.

Authors:  Man-Man Wang; Gong-Sui Wang; Feng Shen; Guang-Yu Chen; Qin Pan; Jian-Gao Fan
Journal:  Dig Dis Sci       Date:  2014-05-18       Impact factor: 3.199
View more
  5 in total

1.  Hepatic steatosis in chronic hepatitis B: a study of metabolic and genetic factors.

Authors:  Michael O Baclig; Karen G Reyes; Veni R Liles; Cynthia A Mapua; Mark Pierre S Dimamay; Juliet Gopez-Cervantes
Journal:  Int J Mol Epidemiol Genet       Date:  2018-04-05

2.  Safety and Effectiveness of Essential Phospholipids Paste in Patients with Non-alcoholic Fatty Liver Disease or Viral Hepatitis.

Authors:  Vladimir T Ivashkin; Igor V Maev; Chavdar S Pavlov; Marina V Mayevskaya; Aleksey A Samsonov; Lyudmila K Palgova; Kirill M Starostin
Journal:  Turk J Gastroenterol       Date:  2021-09       Impact factor: 1.555

3.  Quantification of hepatic steatosis in chronic liver disease using novel automated method of second harmonic generation and two-photon excited fluorescence.

Authors:  George Boon-Bee Goh; Wei Qiang Leow; Shen Liang; Wei Keat Wan; Tony Kiat Hon Lim; Chee Kiat Tan; Pik Eu Chang
Journal:  Sci Rep       Date:  2019-02-27       Impact factor: 4.379

4.  Presence of Hepatic Steatosis Does Not Increase the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Over Long Follow-Up.

Authors:  Chong Teik Lim; George Boon Bee Goh; Huihua Li; Tony Kiat-Hon Lim; Wei Qiang Leow; Wei Keat Wan; Rafay Azhar; Wan Cheng Chow; Rajneesh Kumar
Journal:  Microbiol Insights       Date:  2020-05-13

Review 5.  Immunological Considerations for Schistosoma Vaccine Development: Transitioning to Endemic Settings.

Authors:  Emmanuella Driciru; Jan Pieter R Koopman; Stephen Cose; Afzal A Siddiqui; Maria Yazdanbakhsh; Alison M Elliott; Meta Roestenberg
Journal:  Front Immunol       Date:  2021-03-04       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.